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Homocysteine (HCY) is a pro-inflammatory sulphur-containing redox active endogenous
amino acid, which concentration increases in neurodegenerative disorders including
amyotrophic lateral sclerosis (ALS). A widely held view suggests that HCY could
contribute to neurodegeneration via promotion of oxidative stress. However, the action of
HCY on motor nerve terminals has not been investigated so far. We previously reported
that oxidative stress inhibited synaptic transmission at the neuromuscular junction,
targeting primarily the motor nerve terminals. In the current study, we investigated
the effect of HCY on oxidative stress-induced impairment of transmitter release at
the mouse diaphragm muscle. The mild oxidant H2O2 decreased the intensity of
spontaneous quantum release from nerve terminals (measured as the frequency of
miniature endplate potentials, MEPPs) without changes in the amplitude of MEPPs,
indicating a presynaptic effect. Pre-treatment with HCY for 2 h only slightly affected
both amplitude and frequency of MEPPs but increased the inhibitory potency of H2O2
almost two fold. As HCY can activate certain subtypes of glutamate N-methyl D-
aspartate (NMDA) receptors we tested the role of NMDA receptors in the sensitizing
action of HCY. Remarkably, the selective blocker of NMDA receptors, AP-5 completely
removed the sensitizing effect of HCY on the H2O2-induced presynaptic depressant
effect. Thus, at the mammalian neuromuscular junction HCY largely increases the
inhibitory effect of oxidative stress on transmitter release, via NMDA receptors activation.
This combined effect of HCY and local oxidative stress can specifically contribute
to the damage of presynaptic terminals in neurodegenerative motoneuron diseases,
including ALS.
Keywords: amyotrophic lateral sclerosis, neuromuscular junction, homocysteine, oxidative stress, NMDA
receptors
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Introduction
Homocysteine (HCY, 2-amino-4-sulfanylbutanoic acid) is a
sulphur-containing endogenous amino acid, which is produced
in the methylation cycle of protein metabolism and involved
in maintaining the cells redox balance. An elevated plasma
level of HCY (termed hyperhomocysteinemia, hHCY) markedly
decreases cell viability (Kolling et al., 2013). Extremely high
HCY levels (up to 200 µM) has been found in some
patients with disrupted HCY metabolism, and is believed
to be at the root of certain vascular disorders including
stroke and coronary occlusions (Kang et al., 1992; Stanger
et al., 2009). According to a number of studies, abnormally
elevated levels of HCY in plasma and cerebrospinal fluids
correlate with amyotrophic lateral sclerosis (ALS), a motor
neuronal disease that causes muscle degeneration (Zoccolella
et al., 2008, 2010; Levin et al., 2010; Valentino et al., 2010;
Veeranki and Tyagi, 2013). Inherited deficiency of the enzyme
methylenetetrahydrofolate reductase (MTHFR), transforming
HCY into methionine through remethylation, is associated with
severe muscular hypotonia (Huemer et al., 2015). There is
conflicting evidence about the role of the frequent MTHFR
C677T polymorphisms as risk factors for ALS (Kühnlein et al.,
2011; Ricci et al., 2012; Sazci et al., 2012). The variant MTHFR
C677T, known to be associated with increased levels of HCY
(Kang et al., 1988; Li et al., 2003) is more frequent among ALS
patients (Kühnlein et al., 2011), however an Italian population
study found no association (Ricci et al., 2012). Apart from
a direct link between MTHFR and ALS, there are other
possible mechanisms how the increasing level of HCY due
to aging or improper diet (Zhang et al., 2008; Song et al.,
2013) can speed up the development of disease in patients
with ALS.
Recently, a link of the other Ca2+-dependent enzyme
transglutaminase 2 with several neurodegenerative diseases
including ALS has been proposed in a study showing HCY-
induced activation of THP-1 monocytes associated with
oxidative stress (Gurrò et al., 2015).
The role of HCY in ALS is supported by several studies
showing the beneficial effects of folate or vitamin B12/B6
treatments (Zhang et al., 2008; Song et al., 2013), which are
well known most efficient approaches to lower the level of
endogenous HCY. In line, a large-scale human trial on the action
of methylcobalamin in ALS patients is currently ongoing (Ikeda
et al., 2015).
According to the ‘‘dying-back’’ hypothesis of ALS (Moloney
et al., 2014; Pollari et al., 2014) the dysfunction of nerve
terminals precedes pathological neurodegenerative changes in
a motoneuron. One of the commonly reported mechanisms
of HCY action is the enhanced production of reactive oxygen
species (ROS; Loureiro et al., 2010; Lee et al., 2013; Veeranki
and Tyagi, 2013). In the neuromuscular junction oxidative
stress induced by hydrogen peroxide (H2O2) inhibits synaptic
transmission at the presynaptic site (Giniatullin and Giniatullin,
2003; Giniatullin et al., 2006). The role of oxidative stress
in degeneration of the neuromuscular junction in ALS was
reviewed by us recently in the frame of this research topic
(Pollari et al., 2014). However, despite the recent reports
that hHCY is associated with impaired muscle functions
(Swart et al., 2013; de Jager, 2014) the action of HCY on
neuromuscular transmission and its role in the oxidative
damage of motor nerve terminals has not been investigated
so far.
Thus, the first aim of the current study was to test the ability
of HCY to promote the depressant action of ROS on synaptic
transmission using isolated neuromuscular junctions.
Several independent observations are pointing towards a
potential correlation between enhanced glutamate receptor
signaling and ALS progression. In the nervous system,
extracellular HCY is able to stimulate the glutamate N-methyl
D-aspartate (NMDA) receptor (Lipton et al., 1997; Poddar
and Paul, 2013; Abushik et al., 2014). Homocysteinic acid, an
analog of HCY with potent agonist activity on NMDA receptors
triggers calcium accumulation in motor neurons (Adalbert
et al., 2002). Increased glutamate levels were found in blood
plasma of patients with ALS (Cecchi et al., 2014). A presynaptic
glutamate release inhibitor Riluzole applied to ALS patients as
a medical treatment extends life by 3–5 months (Miller et al.,
2012) suggesting a role of glutamate receptors in the progression
of this disease.
At the mammalian neuromuscular junction both NR1 and
NR2A subunits of NMDA receptor have been found (Mays
et al., 2009). In rats, the inhibition of NMDA receptors
suppressed contractions of the diaphragm muscle, without
changing acetylcholine (ACh) signaling (Koyuncuog˘lu et al.,
1998). Hyperactivation of NMDA receptors is often associated
with oxidative stress (Lee et al., 2013), calcium overload and ROS
generation (Ratan and Baraban, 1995). Thus, the second aim of
this study was to test the involvement of muscle NMDA receptors
in synaptic action of HCY and ROS. For this aim, the effect of
HCY and H2O2 on transmitter release was investigated at the
mouse neuromuscular junctions pre-treated with the selective
blocker of NMDA receptors.
Materials and Methods
Preparation and Solutions
Experiments were performed on isolated mice phrenic
nerve—diaphragm preparations kept at room (22–23◦C)
temperature. Mice (BALB/c strain) of both sexes of 20–25 g
body weight were euthanized in accordance with regulations
of the European Community Council Directive (September 22,
2010; 2010/63/EEC). Animal experiments were approved
by the Ethical Committee of the University of Eastern
Finland. Preparations were placed in a small 3.5-ml volume
chamber and continuously superfused with gassed (95%
O2/5% CO2) physiological solution containing (in mM):
NaCl 120; KCl 5; CaCl2 2; NaHCO324; NaHPO4 1; MgCl2 1;
glucose 11, at pH 7.3–7.4. All reagents were purchased from
Sigma-Aldrich (St. Louis, MO, USA) and were dissolved
directly before the use. We used D, L-HCY with expected
∼50% of the natural active L-form of HCY (Lipton
et al., 1997). Drugs were applied via bath perfusion (rate
∼ 2 ml/min).
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Electrophysiology
Miniature end-plate potentials (MEPPs) recorded by
microelectrodes (resistance 5–8 MΩ; filled with 3 mM KCl)
as shown in details in Naumenko et al. (2011). In brief, MEPPs
were acquired using the data acquisition board NI PCI6221
(National Instruments, Austin, TX, USA), visualized with
WinEDR V3.2.7 software (Strathclyde University, UK), digitally
stored at 50 kHz. Off-line amplitudes and interevent intervals of
MEPPs were analyzed with the WinEDR V3.2.7 and ClampFit
V10.2.0.14 (Molecular Devices, Sunnyvale, CA, USA) software.
Subsequent statistical analysis was made using the Origin
graphic software (Origin Lab Corp, Northampton, MA, USA).
MEPPs were collected during 3 min from each of 8–10 synapses
at the same muscle preparation to calculate mean values of
amplitudes and frequencies in control solution and after 30–35
min application of 300 µM H2O2. Muscle fibers with a resting
membrane potential less negative than −60 mV were rejected
from further analysis.
Statistical Analysis
In each experimental series H2O2 effect was counted by
comparing the mean MEPP frequencies and amplitudes before
and after ROS application (30–35 min). Mean values before
H2O2 were taken as 100%. The data are presented as the mean
± SEM (n = number of synapses with indication of number
of animals used). Statistical significance was assessed by using
Student’s t-test (for parametric data) or Mann-Whitney test (for
nonparametric data). Differences were considered significant
when p< 0.05.
Results
We first tested the action of acute oxidative stress on transmitter
release in control conditions. MEPPs representing spontaneous
release of ACh quanta from nerve terminals occurred at a mean
frequency of 0.60 ± 0.05 s−1 and an amplitude of 0.52 ± 0.02
mV (n = 46 synapses/6 mice). These quantal events are classical
readouts of the functional state of the motor synapse when the
frequency of MEPPs reflects the presynaptic function whereas
the amplitude of MEPPs characterizes the functional state of the
postsynaptic membrane (Fatt and Katz, 1952). To model acute
oxidative stress we used the mild oxidant H2O2 in concentration
of 300 µM. Based on our previous experience (Giniatullin
et al., 2006) we considered this concentration efficient and
safe. H2O2 applied via bath perfusion significantly reduced
the frequency of MEPPs (Figures 1A,C,D). After 30–35 min
exposure to H2O2 the mean frequency of MEPPs decreased by
32.3 ± 8.6% (n = 47 synapses/6 mice, p < 0.05 by Mann-
Whitney test) regarding control untreated preparation. No
changes were observed in MEPP amplitudes (47 synapses/6 mice,
p > 0.05; Figures 1A–D) indicating a pure presynaptic effect of
H2O2.
The temporal characteristics of MEPP were not changed by
H2O2. Thus, the rise-time in control was 0.20 ± 0.01 ms (n = 47
synapses/6 mice) and the decay time constant of MEPP was
3.18 ± 0.28 ms (n = 44 synapses/5 mice). After H2O2 treatment
these parameters remained unchanged (95 ± 7% and 94 ±
8% from control values, respectively, n = 44 synapses/5 mice,
p> 0.05).
FIGURE 1 | H2O2 inhibitory action on spontaneous acetylcholine (ACh) release from nerve endings at intact and homocysteine (HCY) pre-treated
mice diaphragms. (A) Representative traces of MEPPs in control, after 300 µM H2O2 application at intact and pre-treated by HCY (500 µM, 2 h) diaphragm
muscles. (B) MEPP shapes before, 30–35 min after application of 300 µM H2O2 in intact and pre-incubated with HCY (500 µM, for 2 h) preparations. Average of
25–30 MEPPs. (C) Cumulative curves of MEPP frequencies and amplitudes in control and after H2O2 application at intact and HCY pre-treated muscles. (D) The top
panel—mean MEPP frequencies in the presence of 300 µM H2O2 at intact (n = 47 synapses/6 mice), and HCY-pre-incubated (n = 55 synapses/7 mice) muscles
compared to the frequency level before H2O2 application (taken as 100%), ∗p < 0.05; the bottom panel—mean MEPP amplitudes (mV) before, 30–35 min after
application of 300 µM H2O2 in intact (n = 47 synapses/6 mice) and pre-incubated with HCY (500 µM, for 2 h; n = 55 synapses/7 mice) preparations, ns = non
significant.
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Next, we tested the action of HCY on spontaneous ACh
release and whether this exposure changed the inhibitory effect
of H2O2. As we intended to model naturally long-lasting
hHCY in the short time window we selected the relatively
large concentration of HCY of 500 µM which nevertheless
corresponds the severe hHCY in humans (Kang et al., 1992;
Stanger et al., 2009). Notably, as we used the racemic D, L-form
of HCY, the effective concentration of the naturally occurring
L-form was actually only half of the total (Lipton et al., 1997).
Nevertheless, after incubation of the neuromuscular preparations
for 2 h in solution containing 500 µM HCY, the mean frequency
of MEPPs was the same as in untreated preparations (+5.8
± 9.0% change comparing with untreated samples; n = 56
synapses/6 mice). No changes were observed in the amplitudes
of MEPPs (Figures 1A–D) and in the time-course of MEPPs
(Figure 1B) after HCY exposure (rise-time = 94 ± 5% and the
decay time constant = 95 ± 7%, p > 0.05, n = 49 synapses/
6 mice).
However, after HCY pre-treatment (500 µM, 2 h) the
inhibitory potency of H2O2 was largely increased. MEPPs
frequency decreased by 60.0 ± 3.6% from the level in the
presence of HCY before H2O2 application (n = 55 synapses/7
mice, p < 0.05; Figures 1A–D). Thus, the depressant effect of
H2O2 on spontaneous ACh release was significantly (p < 0.05
by Mann-Whitney test) more (almost two times) efficient after
muscles exposure to HCY compared to the action of H2O2
alone. No changes were observed in the amplitudes of MEPPs
(Figures 1A–D). Thus, HCY largely amplified the impairment of
motor nerve terminals induced by acute oxidative stress.
Next, we explored potential mechanisms underlying the
sensitizing effect of HCY. As we (Abushik et al., 2014) and others
(Lipton et al., 1997; Poddar and Paul, 2013) showed that HCY
can act via activation of NMDA receptors we next tested the
role of these receptors in the sensitizing action of HCY. Several
previous reports indicated the presence of NMDA receptors at
the neuromuscular junction (Grozdanovic and Gossrau, 1998;
Mays et al., 2009; Malomouzh et al., 2011; Walder et al.,
2013). In these experiments we applied H2O2 after 20 min
pre-incubation with the selective NMDA receptor blocker AP-
5 (50 µM, Abushik et al., 2014), following by incubation of
muscles with a mixture of 50 µM AP-5 and 500 µM HCY
for 2 h. Remarkably, H2O2 (300 µM) applied after muscle
incubation in the mixture of AP-5 plus HCY did not cause
the depressant action on spontaneous ACh release from nerve
endings (Figures 2A,B). Thus, MEPPs frequency in 30–35 min of
H2O2 exposure was even by 8.8± 11.1% higher than control level
after exposure to AP-5 + HCY (n = 53 synapses/6 mice, p> 0.05).
However, a similar insignificant trend (10 ± 7% change, n = 48
synapses/5 mice, P = 0.85) was also observed when AP-5 was
applied to the muscle alone (Figure 2B). MEPP amplitudes were
not significantly changed by H2O2 applied after pre-exposure to
AP-5 + HCY (Figures 2A,C). Likewise, MEPPs kinetics was not
significantly changed (rise-time = 96 ± 6% and the decay time
constant = 94 ± 8% of control values in AP-5 + HCY, n = 53
synapses/6 mice, p> 0.05).
The results of these experiments indicated NMDA receptor-
mediated mechanism of sensitizing action of HCY.
Discussion
The main finding of our study is that the redox active HCY
increases the vulnerability of the mammalian neuromuscular
junction to the inhibitory action of ROS via a glutamatergic
mechanism. This finding uncovers a novel plausible mechanism
for peripheral synaptic impairments, which may be relevant to
motor neuron diseases such as ALS, as these disorders can be
associated with hHCY and with oxidative stress. By modeling
these conditions, our study suggests a new explanation for why
motoneurons (and their peripheral parts) are more vulnerable to
ALS associated with hHCY than other type of neurons.
There is strong evidence of the development of oxidative
stress and of the detrimental role of ROS in ALS (reviewed in
Pollari et al., 2014). At the neuromuscular junction, ROS are
primarily generated at postsynaptic sites during intense muscle
activity (Jackson, 2008) and can be induced via presynaptic
mitochondria activity (David and Barrett, 2003; see also
Figure 3). Dysfunction of mitochondria and Ca2+ dysregulation
contribute to the muscle denervation and motor neuron death
that occur in mouse models of ALS (Jaiswal, 2013; Barrett et al.,
2014).
The presynaptic transmitter releasing machinery is the
most redox-sensitive part of the motor synapse (Giniatullin
and Giniatullin, 2003; Giniatullin et al., 2006) and such a
mechanism probably contributes to the muscle fatigue during the
development of ALS (Pollari et al., 2014).
Despite the recent report that hHCY is associated with
impaired muscle functions (Swart et al., 2013; de Jager, 2014)
the action of HCY has not yet been studied directly at the
neuromuscular junction. However, the role of HCY in ALS where
the impairment of the neuromuscular transmission is one of
the early and leading symptoms of the disease is consistently
discussed. Thus, many studies reported the high level of HCY in
ALS (Zoccolella et al., 2008, 2010; Levin et al., 2010; Valentino
et al., 2010; Veeranki and Tyagi, 2013). In particular, high levels
of HCY in both plasma and cerebrospinal fluids were found
to correlate with ALS muscle degeneration (Zoccolella et al.,
2008; Valentino et al., 2010). However, conflicting data should
also be mentioned. Thus, while some authors found a link
between MTHFR C677T polymorphisms as risk factors for ALS
(Kühnlein et al., 2011; Sazci et al., 2012) others (Ricci et al., 2012)
did not detect a direct association between the two.
Although a causal link remains disputable, the simultaneous
presence of hHCY and ALS associated oxidative stress in
nerve terminals could initiate the mechanism of presynaptic
depression observed in the current study. According to this view
there is a ‘‘two keys mechanism’’ when combined HCY and
ROS synergistically impair the presynaptic compartment of the
neuromuscular junction (Figure 3). The attractiveness of this
hypothesis is that it integrates all of the three potential partners of
the neuromuscular junction—muscle fibers, Schwann cells and
nerve terminal which all could be sources of ROS (Figure 3).
HCY induced exacerbation of ALS is supported by clinical
evidence of the favorable effect of HCY-lowering folate and
B12 supplements (Zhang et al., 2008; Song et al., 2013;
Ikeda et al., 2015). One could suggest that the measurement
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FIGURE 2 | Effects of AP-5 and the action of H2O2 on MEPPs after pre-incubation of neuromuscular junctions in HCY or in the mixture of AP-5 and
HCY. (A) MEPPs (top) in muscles pre-incubated in the selective blocker of N-methyl D-aspartate (NMDA) receptors AP-5 (50 µM, for 20 min), following incubation in
a mixture of AP-5 and 500 µM HCY for 2 h, and MEPPs (bottom) after application of 300 µM H2O2 in the presence of AP-5 + HCY. (B) Effects of 50 µM AP-5 alone
and the action of H2O2 on MEPP frequencies in muscles pre-incubated for 2 h in 500 µM HCY and in the mixture of AP-5 and HCY (n = 53 synapses/6 mice,
p > 0.05). MEPPs frequency level in untreated muscle (for AP-5 alone) or the levels in HCY and in AP-5 + HCY before H2O2 application was set as 100%. Notice that
AP-5 largely reduced the inhibitory effect of H2O2 in the presence of HCY, ∗p < 0.05. (C) MEPP amplitudes in AP-5 and before and after 30–35 min application of
300 µM H2O2 to diaphragm muscles pre-incubated in 500 µM HCY and in mixture of 50 µM AP-5 and 500 µM HCY (n = 53 synapses/6 mice), ns = non significant.
of endogenous level of HCY in ALS patients should be
monitored to determine the best type of treatments (and
perhaps prophylaxis). Increase in HCY levels by low plasma
folate or improper nutrition (Kang et al., 1992) might be an
additional overlapping condition aggravating the development
of ALS. Therefore, even though unable to cure ALS alone,
the folic acid therapy could be an important component
of a more complex disease therapy. Another important
implication of our results is that patients with ALS should
avoid nitrous oxide for anaesthesia as the latter could induce
an acute burst of HCY (Asghar and Ali, 2012; Morris et al.,
2015).
Interestingly, increased total HCY levels can be detected
in a variety of neurological diseases such as stroke (Kang
et al., 1992), Alzheimer’s disease and other types of dementia
(Isobe et al., 2005; de Jager, 2014), psychiatric disorders or
infections such sepsis (Ploder et al., 2010) without reported
signs of ALS symptomatology. This raises a question: why
would ALS symptomatology develop only in this specific
group of patients? To answer to this question we propose a
working hypothesis based on the main finding of the current
study: the interaction between ROS and HCY, that whereas
hHCY is not specific to ALS (being observed in other above-
mentioned diseases) the coincidence of hHCY and oxidative
damage locally in the peripheral part of the motoneuron
is specific to ALS. In addition, the level of HCY is almost
10 times higher in blood than in the CSF (Valentino et al.,
2010) suggesting a higher probability of HCY-mediated toxicity
in peripheral tissues such as nerve endings in the skeletal
muscle. Thus, our hypothesis can provide a novel explanation
of why peripheral endings of the motoneuron are more
vulnerable to ALS than central neurons affected by other brain
diseases.
In the current study, in order to model the detrimental
effects of HCY in a short time frame we used high concentrations
of the D-L form of HCY. In fact, the actual concentration of
the active L-form of HCY (Lipton et al., 1997) in our
experiments is at least two times lower (∼250 µM) which
is close to what is observed in severe hHCY (Kang et al.,
1992; Stanger et al., 2009). Notably, even at such high
concentrations HCY did not significantly affect neuromuscular
transmission parameters per se. The accuracy of measurement
of the fraction of total and free HCY in pathological
states is still a matter of debate (Adam et al., 2013). It
is also worth noting that, in addition to HCY, a related
endogenous compound homocystine is present in the blood
(Zhang et al., 2014), and its molecular targets deserve future
studies.
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FIGURE 3 | Schematic presentation of the model proposed for the combined damaging action of hyperhomocysteinemia (hHCY) and oxidative stress
to motor nerve terminals. (A) Healthy (normal low level of HCY) neuromuscular junction comprising motor nerve terminals, surrounding Schwann cells and
muscles fibers. reactive oxygen species (ROS) generated via mitochondria are mostly neutralized by the endogenous antioxidant mechanisms. All this provided high
level of transmitter release from presynaptic active zones. (B) Compromised motor nerve terminals in amyotrophic lateral sclerosis (ALS) associated with hHCY due
to polymorphism of MTHFR, deficiency of cystathionine beta-synthase (CBS) or improper diet (low folate or B12). Notice the reduced number of active zone and
synaptic vesicles and compromised mitochondria at different levels (muscle, nerve and Schwann cells) generating increased level of ROS. Activation of postsynaptic
NMDA receptors by high HCY assisted by the co-agonist D-serine released from glial cells can lead to Ca2+-dependent induction of NO, known as a strong
presynaptic inhibitor by itself and partner in generation of toxic ONOO−.
The main finding of the current study was that the exposure
to HCY largely promoted the presynaptic inhibitory action
of H2O2. Moreover, in our study we provide a mechanistical
explanation for this phenomenon identifying the key role
of glutamate NMDA receptors in the sensitizing effect of
HCY. Indeed, the selective blocker of NMDA receptors AP-5
completely prevented the additive effect of HCY on the inhibition
of transmitter release by H2O2. Our finding is consistent with
previous studies showing that HCY induces excitotoxic effects
mainly in cells expressing NMDA receptors (Boldyrev et al.,
2013). Activation of NMDA receptors by HCY results in an
increase of cytoplasmic Ca2+ and ROS accumulation (Loureiro
et al., 2010; Leal and Gomes, 2015) which all are likely happening
in skeletal muscle during hHCY (Figure 3).
Glutamate ionotropic receptors are located at vertebrate
neuromuscular junctions (Grozdanovic and Gossrau, 1998).
Knockouts of NMDA receptor subunits in mice induces
phenotypes which are similar to those typically associated with
neuromuscular disorders (Single et al., 2000; Meng et al.,
2003). The presence of AP-5 sensitive NMDA receptors in the
muscle has been shown in several previous studies involving
immunolabeling and electrophysiological recordings (Mays et al.,
2009; Malomouzh et al., 2011; Walder et al., 2013). However,
in contrast to the high diversity of glutamate receptor subunits
observed in the CNS, only a limited number of glutamate
receptor subunit types is expressed in the neuromuscular
junction (Mays et al., 2009). As we did not see changes in
the amplitude of MEPPs, we suggest only limited and probably
diffuse expression of postsynaptic NMDA receptors in skeletal
muscle.
Downstream NMDA receptor signaling pathway could
involve the highly diffusible messenger NO (Figure 3). It is
known that in neurons, glutamate, acting on post-synaptic
NMDA receptors can induce NO release as nitric oxide synthase
is a part of the NMDA/NOS complex (Courtney et al., 2014).
Consistent with this, HCY neurotoxicity could be due to the
release of NO (Stamler et al., 1993) which is a potent inhibitor of
ACh release from motor nerve endings (Giniatullin et al., 2005;
Valiullina and Sitdikova, 2012). Early studies indicate that the
activation of muscle NMDA receptors by bath-applied glutamate
increases synthesis of NO in muscle fibers and NO acts in a
retrograde manner on motor nerve terminals to inhibit non-
quantal release of ACh (Malomouzh et al., 2003).
NO can also cooperate with superoxide to produce the
strong oxidant, peroxynitrite, which is considered as a candidate
inducer of cell death in ALS (Urushitani and Shimohama,
2001). Whereas the involvement of NO in HCY induced
sensitizing effects require further investigations, especially taking
into account potential species-dependent action of NMDA/NO
mediated signaling which could explain the fact that the
retrograde presynaptic inhibition by ROS pre-conditioned by
HCY was prevented by the NMDA antagonist AP-5.
Schwann cells surrounding nerve terminals could be
additional contributors to the impaired presynaptic function
(Pollari et al., 2014) via release of gliotransmitters (Araque
et al., 2014) including D-serine (Wu et al., 2005; see also
Figure 3). Glial cells D-serine like glycine can potentiate the
neurotoxicity of HCY via the glycine binging site of NNDA
receptor (Wolosker, 2007; McCully, 2009; see also Figure 3B). In
line with this, D-serine can contribute to the pathophysiology of
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familial ALS associated with the R199W mutation in D-amino
acid oxidase (Paul and de Belleroche, 2015).
In summary, we show here that motor nerve terminals are
highly vulnerable to the combined action of HCY and oxidative
stress, both of which can be present in ALS and likely contribute
together to the presynaptic impairment of the neuromuscular
function. Thus, we propose a model, which may be relevant for
ALS and raises a number of important questions with significant
translational impact, which could be investigated further in
animal ALS models and in future clinical studies.
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